drugset / Trial / NCT00686933

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00686933

Phase 2 Completed 117 enrolled AbbVie
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

Timeline

Start
2008-05
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Pozanicline Small molecule 80 mg